S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in

Conversion Labs Stock Forecast, Price & News

-1.82 (-11.17 %)
(As of 03/4/2021 12:00 AM ET)
Today's Range
Now: $14.48
50-Day Range
MA: $20.50
52-Week Range
Now: $14.48
Volume1.50 million shs
Average Volume1.05 million shs
Market Capitalization$335.66 million
P/E RatioN/A
Dividend YieldN/A
Conversion Labs, Inc. operates as a direct response healthcare company that provides over the counter products and prescription medications to consumers worldwide. The company's products include Shapiro MD, a shampoo, conditioner, and leave-in-foamer for treating hair loss; iNR Wellness MD, a nutritional supplement for immune and gut support; RexMD for the treatment of cold sores, mental health, and various other medical conditions faced by men; SOSRx, a telemedicine brand that offers prescription medications and over-the-counter emergency preparation supplies for disaster situations, such as flu epidemics, bacterial outbreaks, bioterrorism and water supply failures, and others; and PDFSimpli, a PDF conversion software enables users to convert, edit, and sign PDF documents. It markets and sells its products through advertisements on Facebook, Google, Amazon, and other social media and e-commerce platforms. The company was formerly known as Immudyne, Inc. and changed its name to Conversion Labs, Inc. in June 2018. Conversion Labs, Inc. was founded in 1994 and is based in New York, New York.
Conversion Labs logo


LifeMD Inc
February 26, 2021 |  reuters.com
Conversion Labs reports Q3 prelim
October 12, 2020 |  seekingalpha.com
Conversion Lab receives $3.5M from strategic investors
August 31, 2020 |  seekingalpha.com
See More Headlines

Industry, Sector and Symbol

Industry Miscellaneous manufacturing industries
Current SymbolNASDAQ:CVLB
Phone(866) 351-5907
Year FoundedN/A



Sales & Book Value

Annual Sales$12.47 million
Book Value($0.11) per share


Net Income$-3,140,000.00


Market Cap$335.66 million
Next Earnings Date3/30/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

1.87 out of 5 stars

Retail/Wholesale Sector

40th out of 383 stocks

Miscellaneous Manufacturing Industries Industry

4th out of 23 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
-1.82 (-11.17 %)
(As of 03/4/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CVLB News and Ratings via Email

Sign-up to receive the latest news and ratings for CVLB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Conversion Labs (NASDAQ:CVLB) Frequently Asked Questions

Is Conversion Labs a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Conversion Labs in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Conversion Labs stock.
View analyst ratings for Conversion Labs
or view top-rated stocks.

What stocks does MarketBeat like better than Conversion Labs?

Wall Street analysts have given Conversion Labs a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Conversion Labs wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Conversion Labs?

Conversion Labs saw a increase in short interest in January. As of January 29th, there was short interest totaling 225,400 shares, an increase of 229.5% from the January 14th total of 68,400 shares. Based on an average daily trading volume, of 531,200 shares, the short-interest ratio is currently 0.4 days. Currently, 2.4% of the shares of the stock are short sold.
View Conversion Labs' Short Interest

When is Conversion Labs' next earnings date?

Conversion Labs is scheduled to release its next quarterly earnings announcement on Tuesday, March 30th 2021.
View our earnings forecast for Conversion Labs

How has Conversion Labs' stock been impacted by Coronavirus (COVID-19)?

Conversion Labs' stock was trading at $0.1269 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CVLB stock has increased by 11,310.6% and is now trading at $14.48.
View which stocks have been most impacted by COVID-19

What price target have analysts set for CVLB?

2 Wall Street analysts have issued 12 month price targets for Conversion Labs' shares. Their forecasts range from $35.00 to $40.00. On average, they anticipate Conversion Labs' share price to reach $37.50 in the next twelve months. This suggests a possible upside of 159.0% from the stock's current price.
View analysts' price targets for Conversion Labs
or view top-rated stocks among Wall Street analysts.

Who are Conversion Labs' key executives?

Conversion Labs' management team includes the following people:
  • Mr. Justin Schreiber, Pres, CEO & Chairman (Age 38, Pay $52k)
  • Mr. Juan Manuel Piñeiro Dagnery, Chief Financial Officer (Age 34, Pay $111.97k)
  • Mr. Stefan Galluppi, CTO & Director (Age 34, Pay $111k)
  • Mr. Sean Fitzpatrick, Pres of LegalSimpli Software LLC (Age 38, Pay $119.27k)
  • Mr. Brad Roberts, Chief Operating Officer (Age 41)
  • Mr. Eric H. Yecies, Chief Compliance Officer & Gen. Counsel (Age 43)
  • Dr. Joseph V. DiTrolio, Chief Medical Officer of US & Independent Director (Age 70)
  • Mr. Bryant Patrick Hussey, Chief Digital Officer
  • Dr. Anthony David Puopolo II, Chief Medical Officer

Who are some of Conversion Labs' key competitors?

What is Conversion Labs' stock symbol?

Conversion Labs trades on the NASDAQ under the ticker symbol "CVLB."

Who are Conversion Labs' major shareholders?

Conversion Labs' stock is owned by many different institutional and retail investors. Top institutional investors include Monashee Investment Management LLC (1.82%), Barry Investment Advisors LLC (0.36%), Magnus Financial Group LLC (0.20%), HighTower Advisors LLC (0.11%) and Diametric Capital LP (0.04%). Company insiders that own Conversion Labs stock include Brad Michael Roberts, Happy David Walters, Justin Schreiber and Stefan Galluppi.
View institutional ownership trends for Conversion Labs

Which institutional investors are buying Conversion Labs stock?

CVLB stock was acquired by a variety of institutional investors in the last quarter, including Monashee Investment Management LLC, Barry Investment Advisors LLC, Magnus Financial Group LLC, HighTower Advisors LLC, and Diametric Capital LP. Company insiders that have bought Conversion Labs stock in the last two years include Brad Michael Roberts, Happy David Walters, Justin Schreiber, and Stefan Galluppi.
View insider buying and selling activity for Conversion Labs
or or view top insider-buying stocks.

How do I buy shares of Conversion Labs?

Shares of CVLB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Conversion Labs' stock price today?

One share of CVLB stock can currently be purchased for approximately $14.48.

How much money does Conversion Labs make?

Conversion Labs has a market capitalization of $335.66 million and generates $12.47 million in revenue each year.

How many employees does Conversion Labs have?

Conversion Labs employs 26 workers across the globe.

What is Conversion Labs' official website?

The official website for Conversion Labs is www.conversionlabs.com.

Where are Conversion Labs' headquarters?

Conversion Labs is headquartered at 800 THIRD AVENUE SUITE 2800, NEW YORK NY, 10022.

How can I contact Conversion Labs?

Conversion Labs' mailing address is 800 THIRD AVENUE SUITE 2800, NEW YORK NY, 10022. The company can be reached via phone at (866) 351-5907 or via email at [email protected]

This page was last updated on 3/6/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.